Chronic Fatigue Syndrome Research Program

There currently exists no FDA approved treatment for Chronic Fatigue Syndrome (CFS). K-PAX Pharmaceuticals is currently developing what we hope will become the first by-prescription treatment for this condition. A multi-center double-blind, placebo-controlled trial is currently projected to begin enrolling patients in September 2013. Check here for more information or call 1-855-318-4673.

HIV/AIDS Research Program

For more information on the ongoing Canadian HIV/AIDS Study (The MAINTAIN Study) using K-PAX IMMUNE for people with early HIV infection, which is currently enrolling patients, please click here.

K-PAX Immune Support Formula was the micronutrient formula tested in a double-blinded, placebo-controlled clinical trial which demonstrated a positive effect on the immune systems of HIV(+) individuals on antiviral therapy.

Forty HIV-infected patients taking a stable antiviral medication regimen were randomized to either the K-PAX formula or placebo groups. After 12 weeks, the patients taking the K-PAX formula experienced an average 24% increase in their CD4 count compared to no change in the placebo group (P=0.01).

The mean absolute CD4 count also rose significantly by an average of 65 cells after 12 weeks in the micronutrient group versus a 6 cell decline in the placebo group (P=0.029).

This research study was presented at the 2006 World AIDS Conference in Toronto (Abstract #0402). It was also published in the August 2006 issue of the Journal of Acquired Immune Deficiency Syndromes (JAIDS) - Kaiser JD, et al. JAIDS 2006;42(5):523-528.

To download a copy of this study directly  from the Journal of AIDS website click here

K-PAX IMMUNE and ENERGY are dietary supplements and are not indicated for the diagnosis, prevention, or treatment of any medical condition. Individual results may vary.